Clinical trial
Growth Hormone Treatment in Short Children Born Small for Gestational Age
NCT00191529 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191529 |
|---|---|
| Title | Growth Hormone Treatment in Short Children Born Small for Gestational Age |
| Official title | Optimization of Growth Hormone Treatment in Short Children Born Small for Gestational Age Based on a Growth Prediction Model-The OPTIMA Trial |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infant, Small for Gestational Age |
| Intervention type | Drug |
| Interventions | somatropin |
| Enrollment | 200 |
| Start date | Dec 1, 2002 |
| Completion | Jun 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 15, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: